These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3870983)

  • 1. Optimal control applications in the chemotherapy of multiple myeloma.
    Swan GW
    IMA J Math Appl Med Biol; 1985; 2(3):139-60. PubMed ID: 3870983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General applications of optimal control theory in cancer chemotherapy.
    Swan GW
    IMA J Math Appl Med Biol; 1988; 5(4):303-16. PubMed ID: 3241099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical model for human myeloma relating growth kinetics and drug resistance.
    Hokanson JA; Brown BW; Thompson JR; Jansson B; Drewinko B
    Cell Tissue Kinet; 1986 Jan; 19(1):1-10. PubMed ID: 3955625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
    Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
    Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma: a therapeutic enigma.
    Hoogstraten B
    Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra low dose thalidomide in myeloma revisited.
    Patrick HE; Bowcock SJ
    Br J Haematol; 2010 Jul; 150(2):232-4. PubMed ID: 20346009
    [No Abstract]   [Full Text] [Related]  

  • 10. Does low-dose aspirin have antineoplastic effects in multiple myeloma?
    Baz R; Hussein MA
    Br J Haematol; 2006 Aug; 134(3):349-50. PubMed ID: 16848779
    [No Abstract]   [Full Text] [Related]  

  • 11. Zoledronic acid in myeloma: MRC Myeloma IX.
    Rajkumar SV
    Lancet; 2010 Dec; 376(9757):1965-6. PubMed ID: 21131042
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current status of treatment for multiple myeloma].
    Tsuchiya J
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1911-20. PubMed ID: 7184381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Berenson JR
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):2-4. PubMed ID: 22130220
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal control analysis of a cancer chemotherapy problem.
    Swan GW
    IMA J Math Appl Med Biol; 1987; 4(2):171-84. PubMed ID: 3503092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.
    Alberts DS; Durie BG; Salmon SE
    Cancer Treat Rep; 1977; 61(3):381-8. PubMed ID: 872138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA approves new agent for multiple myeloma.
    Fenichel MP
    J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Avet-Loiseau H; Moreau P; Mohty M
    Leukemia; 2012 Jan; 26(1):73-85. PubMed ID: 22024721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate for early-stage, untreated myeloma.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
    J Clin Oncol; 2003 Aug; 21(16):3177-8; author reply 3178. PubMed ID: 12915612
    [No Abstract]   [Full Text] [Related]  

  • 20. Reinforcement learning-based control of drug dosing for cancer chemotherapy treatment.
    Padmanabhan R; Meskin N; Haddad WM
    Math Biosci; 2017 Nov; 293():11-20. PubMed ID: 28822813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.